FORMULATION AND EVALUATION OF ROFECOXIB LIQUISOLID TABLETS

Abstract

The aim of our study was to improve the availability of Rofecoxib a practically insoluble non-steroidal anti-inflammatory drug, as a model drug by using liquisolid technique. The effect of powder substrate composition on the flowability and compressibility of liquisolid compacts were evaluated. Specifically, several liquisolid formulations, containing 25-mg Rofecoxib, which containing different carrier to coating ratios in their powder substrates and a fixed liquid medication, were prepared. The dissolution profiles of Rofecoxib liquisolid tablets were determined according to USP method. The obtained dissolution profiles were compared to that of a commercial product. In the present study, the formulated liquisolid systems exhibited acceptable flowability and compressibility. In addition, liquisolid tablets displayed significant enhancement of the dissolution profiles compared to this of commercial one.